Anti-aging compositions and methods for using same

Abstract

The invention generally relates to anti-aging compositions and methods for using the anti-aging compositions. In one aspect, the invention provides a method for preventing cellular aging in a cell of a subject, the method comprising the step of providing to the cell an effective amount of at least one lithium compound or a pharmaceutically acceptable salt thereof, and an effective amount of at least one glycyrrhizie triterpenoid compound or a pharmaceutically acceptable salt thereof, thereby preventing the cell from aging. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present invention.

1 . A method for preventing cellular aging in a cell of a subject, the method comprising the step of providing to the cell an effective amount of at least one lithium compound or a pharmaceutically acceptable salt thereof, and an effective amount of at least one glycyrrhizic triterpenoid compound or a pharmaceutically acceptable salt thereof, thereby preventing the cell from aging. 
     
     
         2 . The method of  claim 1 , wherein the least one lithium compound, or a pharmaceutically acceptable salt thereof is selected from lithium chloride, lithium bromide, lithium carbonate, lithium nitrate, lithium sulfate, lithium acetate, lithium lactate, lithium citrate, lithium aspartate, lithium gluconate, lithium malate, lithium ascorbate, lithium orotate, lithium succinate, and combinations thereof. 
     
     
         3 . (canceled) 
     
     
         4 . The method of  claim 1 , wherein the least one glycyrrhizic triterpenoid compound is selected from glycyrrhizin, enoxolone, carbenoxolone, cicloxolone, pharmaceutically acceptable salts thereof, and combinations thereof. 
     
     
         5 . The method of  claim 4 , wherein the least one glycyrrhizic triterpenoid is glycyrrhizin, having the structure represented by the formula: 
       
         
           
           
               
               
           
         
       
     
     
         6 .- 11 . (canceled) 
     
     
         12 . The method of  claim 1 , wherein the cellular anti-aging activity comprises: maintaining cell replication potential; maintaining senescence, maintaining cell cycle-arrested state in post-mitotic cells, stimulating, improving, or maintaining mitochondrial function; preventing deterioration of mitochondria, preventing cell death following senescence deterioration, or a combination thereof. 
     
     
         13 . The method of  claim 1 , wherein the cellular anti-aging activity comprises: activity against at least one component of the TOR (Target of rapamycin) pathway, IGF-I (insulin-like growth factors) receptor pathway, EGFR (epidermal growth factor receptor) pathway, or a combination thereof. 
     
     
         14 . The method of  claim 13 , wherein the cellular anti-aging activity comprises inhibition of at least one component of the TOR (Target of rapamycin) pathway, IGF-I (insulin-like growth factors) receptor pathway, EGFR (epidermal growth factor receptor) pathway, or a combination thereof. 
     
     
         15 . (canceled) 
     
     
         16 . The method of  claim 1 , wherein the cellular anti-aging activity comprises preventing an age-related disease or disorder. 
     
     
         17 . The method of  claim 16 , wherein the age-related disease or disorder is associated with age-related cell loss, loss of mitochondrial function, or loss of telomere function. 
     
     
         18 . The method of  claim 16 , wherein the age-related disease or disorder comprises an abnormal proliferative disease, a degenerative disease, or a function-decreasing disorder. 
     
     
         19 . The method of  claim 16 , wherein the age-related disease or disorder is selected from tumorigenesis, malignant cancer development, myocardial infarction, cerebellar infarction, stroke, Parkinson's disease, heart failure, atherosclerosis, hypertension, cataract, age-related macular degeneration, sarcopenia, osteoarthritis, osteoporosis, loss of bone marrow, multiple sclerosis, Sjogren, Rheumatoid arthritis, decreased immune function, diabetes, idiopathic pulmonary fibrosis, a neurodegenerating disease, Alzheimer's disease, Huntington's disease, and disorders caused by dysfunction in testosterone, estrogen, growth hormone, IGF-I, or energy production. 
     
     
         20 .- 46 . (canceled) 
     
     
         47 . The method of  claim 1 , further comprising the step of providing to the cell an effective amount of at least one retinoic acid compound or a pharmaceutically acceptable salt thereof. 
     
     
         48 . The method of  claim 47 , wherein the at least one retinoic acid compound is selected from all-trans-retinoic 7-cis-retinoic acid, 9-cis-retinoic acid, 11-cis-retinoic acid, and 13-cis-retinoic acid. 
     
     
         49 . (canceled). 
     
     
         50 . A method for the treatment of a subject, the method comprising the steps of:
 a. diagnosing the subject as having an age-related disorder or disease; and   b. administering to the subject an effective amount of at least one lithium compound or a pharmaceutically acceptable salt thereof, and an effective amount of at least one glycyrrhizic triterpenoid compound or a pharmaceutically acceptable salt thereof.   
     
     
         51 .- 56 . (canceled) 
     
     
         57 . The method of  claim 50 , wherein the age-related disease or disorder is associated with age-related cell loss, loss of mitochondrial function, loss of telomere function, an abnormal proliferative disease, a degenerative disease, or a function-decreasing disorder. 
     
     
         58 . (canceled) 
     
     
         59 . The method of  claim 50 , wherein the age-related disease or disorder is selected from tumorigenesis, malignant cancer development, myocardial infarction, cerebellar infarction, stroke, Parkinson's disease, heart failure, atherosclerosis, hypertension, cataract, age-related macular degeneration, sarcopenia, osteoarthritis, osteoporosis, loss of bone marrow, multiple sclerosis, Sjogren, Rheumatoid arthritis, decreased immune function, diabetes, idiopathic pulmonary fibrosis, a neurodegenerating disease, Alzheimer's disease, Huntington's disease, and disorders caused by dysfunction in testosterone, estrogen, growth hormone, IGF-I, or energy production. 
     
     
         60 . The method of  claim 50 , wherein the effective amount of the lithium compound is from about 1 mg to about 50 mg and the effective amount of the glycyrrhizic triterpenoid compound is from about 1 to about 100 mg. 
     
     
         61 . (canceled). 
     
     
         62 . The method of  claim 50 , further comprising administrating to the subject an effective amount of at least one retinoic acid compound or a pharmaceutically acceptable salt thereof. 
     
     
         63 .- 92 . (canceled) 
     
     
         93 . The method of  claim 1 , wherein the effective amount of the lithium compound is from about 1 mg to about 50 mg and the effective amount of the glycyrrhizic triterpenoid compound is from about 1 to about 100 mg.